Key Takeaways:
The US is investigating whether Germany's drug pricing system unfairly penalizes American pharmaceutical companies, opening the door to new tariffs on transatlantic trade.
The US launched a Section 301 trade investigation into Germany's plan to force drugmakers to offer larger discounts on medicines, a move that could lead to fresh tariffs on billions of dollars in pharmaceutical imports.
"The German approach appears to systematically underpay for innovative medicines, and we will examine whether it is unreasonable or discriminatory," Jamieson Greer, the US Trade Representative, said Thursday.
The probe, announced June 18, follows Berlin's decision to tighten its drug pricing framework, which requires manufacturers to negotiate steeper rebates on patented medicines. Germany's system uses reference pricing — comparing a drug's cost to therapeutic alternatives — combined with mandatory discounts negotiated with the national association of statutory health insurers. US drugmakers have long argued these practices effectively cap revenue below market rates.
If the USTR determines the German system violates trade obligations, it could impose tariffs on German pharmaceutical imports, escalating transatlantic trade tensions. German drugmakers including Bayer AG and Merck KGaA count the US as their largest single market. Any tariffs would raise costs for American hospitals and patients while squeezing margins at German manufacturers already facing pricing pressure across Europe.
The Section 301 probe revives a tool the US has deployed primarily against China, most notably during the 2018 trade war that imposed tariffs on more than $300 billion in Chinese goods. Applying it to Germany, a key European ally, signals a significant hardening of the US approach to pharmaceutical pricing and could reshape transatlantic trade dynamics.
The investigation will examine whether Germany's pricing practices constitute a persistent pattern of underpayment that discriminates against US-made drugs. The USTR typically completes Section 301 investigations within 6 to 12 months, including a public comment period and hearings, before making any tariff recommendation.
The probe adds to existing trade friction between the US and Europe. The US has previously threatened tariffs on European goods over digital services taxes and aircraft subsidies, though pharmaceutical products have largely been spared from transatlantic trade disputes.
For German drugmakers, the timing is particularly challenging. Bayer and Merck KGaA are already navigating pricing pressure across Europe, where governments are increasingly adopting cost-containment measures to manage healthcare budgets. A US tariff would compound these pressures, potentially forcing companies to choose between absorbing the cost or passing it to American consumers.
The probe also carries implications for the broader healthcare sector. If the US successfully challenges Germany's pricing model, it could set a precedent for similar actions against other European countries with reference-pricing systems, including France, Italy and Spain. Such an outcome would fundamentally alter the pricing landscape for global pharmaceutical companies.
This article is for informational purposes only and does not constitute investment advice.
